[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bernstein Clinical Research Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":37},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":5},"100578990",false,"NCT06818474","Lanadelumab in Long-term Prophylaxis of Acquired Angioedema","Inclusion Criteria:\n\n* A diagnosis of AAE with recurrent attacks without urticaria (decreased C1INH functional, quantitative levels, decreased C4 and decreased C1q levels, no family history of angioedema), presence of anti-C1INH antibody and\u002For paraproteinemia (e.g. monoclonal gammopathy of unknown significance)\n* historical attack rate of \\>= on attack per month prior to starting tranexamic acid (TAA)\n\nExclusion Criteria:\n\n* History of anaphylaxis or hypersensitivity to biologics\n* History of major systemic disease not well controlled in opinion of the PI\n* Women who are pregnant or breast feeding\n* Concurrent participation in other clinical trials\n* HAE Type 1 or 2 and normal complement HAE","ALL","18 Years",{"count":17,"type":18},5,"ESTIMATED","INTERVENTIONAL",[21],"PHASE4","use of lanadelumab in patients with acquired angioedema",[24],"Angioedema","RECRUITING","2025-02-24",{"date":28,"type":29},"2025-02-25","ACTUAL",{"date":31,"type":29},"2024-06-01",{"date":33,"type":18},"2027-12-01",{"name":35,"class":36},"Bernstein Clinical Research Center","OTHER",""]